Investors pummel Brazil's Dasa for turmoil and sluggish Dx sales

Investors are pummeling one of Brazil's largest providers of medical diagnostics as the company struggles under management turmoil and sluggish sales, Bloomberg reports. Diagnosticos da America SA, or Dasa, endured a 24% drop in trading in São Paulo so far this year, according to the story. Why such a drastic drop? Concerns are growing as the company has worked its way through 7 different CEOs or CFOs so far this year, Raymond James analyst Guilherme Assis told Bloomberg. What would help alleviate the situation, the story explains, is for Dasa to develop a strategy to fuel growth as incomes rise in Brazil and more people migrate from the public health system to private providers. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.